Lombard Odier Asset Management Switzerland SA Has $14.53 Million Holdings in Amgen Inc. $AMGN

Lombard Odier Asset Management Switzerland SA increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 10.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,283 shares of the medical research company’s stock after buying an additional 3,811 shares during the period. Lombard Odier Asset Management Switzerland SA’s holdings in Amgen were worth $14,525,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Robeco Institutional Asset Management B.V. grew its stake in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new position in shares of Amgen during the fourth quarter worth approximately $1,669,000. Adell Harriman & Carpenter Inc. lifted its holdings in shares of Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Amgen in the 4th quarter worth $22,441,000. Finally, Robinhood Asset Management LLC acquired a new stake in Amgen in the 4th quarter valued at $17,526,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 1.2%

Shares of NASDAQ:AMGN opened at $376.04 on Friday. The company has a market capitalization of $202.95 billion, a PE ratio of 26.17, a price-to-earnings-growth ratio of 3.80 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The business has a fifty day moving average price of $351.28 and a two-hundred day moving average price of $351.80. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of recent research reports. Erste Group Bank restated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. BMO Capital Markets reiterated an “outperform” rating and set a $400.00 price objective on shares of Amgen in a report on Wednesday, July 1st. UBS Group boosted their target price on shares of Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Morgan Stanley dropped their price target on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 8th. Finally, Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $356.62.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.